Atavistik Bio has dosed the first subject in its Phase I clinical trial of ATV-1601, designed to treat adults with solid tumours.

Hansa Biosciences’ Idefirix (imlifidase) has reduced patients’ antibodies to a level that allows dosing in patients with Duchenne muscular dystrophy (DMD) with Sarepta and Roche’s Elevidys ...

Roche’s Genentech has reported new five-year data from the Phase III Portal trial of Susvimo for treating wet AMD.

Eli Lilly's Jaypirca met its non-inferiority primary endpoint, trumping Imbruvica in patient overall response rate (ORR).

Lantern Pharma has completed targeted enrolment for its multi-centre Phase II HARMONIC trial of a disulfide small molecule, LP-300.

Cognition Therapeutics’ therapy showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients.

Anavex's blarcasemine met its primary endpoints, improving cognition and function over a four year period in early-stage Alzheimer’s patients.

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

Eli Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after over three years of treatment.

Idiopathic pulmonary fibrosis (IPF) is a progressive and often fatal lung disease characterised by the accumulation of scar tissue in the lungs, leading to respiratory failure.

The Phase Ib trial only showed two patients achieving partial response and three achieving stable disease. Image credit: mi_viri / Shutterstock Nuvectis Pharma is terminating development of NXP800 in ...

The therapy is designed for sustained delivery to treat vascular endothelial growth factor-mediated retinal conditions. Credit: Mangza2029 / Shutterstock.com. EyePoint Pharmaceuticals has concluded ...